TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9313757
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous insulin infusion
Study: 9313757
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous insulin infusion and Intensive insulin therapy
Study: 3780088
Drug: Intraarticular methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular methylprednisolone (40 mg)
Study: 30048006
Drug: 2 repeated
Normalized name: EICOSYL POVIDONE (2 EICOSYL BRANCHES/REPEAT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 repeated intrathecal injections of autologous bone marrow–derived mesenchymal stem cells (BM‐MSCs)
Study: 27797708
Drug: Hesperidin 2S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hesperidin 2S (450 mg/d)
Study: 24325594
Drug: Constraint‐induced movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐induced movement therapy (CIMT) program
Study: 24325594
Drug: Conventional non‐structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional non‐structured therapy program (control group)
Study: 22890117
Drug: S(+)‐ketamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine (20 mg/70 kg for the first hour, 40 mg/70 kg for the second hour)
Study: 16212446
Drug: clinic-directed group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinic-directed group, replicating the parameters of the early intensive behavioral treatment developed at UCLA
Study: 1446477
Drug: Increased inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased inhaled corticosteroid (mean 1478 micrograms daily)
Study: 1446477
Drug: Regular inhaled
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhaled bronchodilator (on-demand beta-agonist)
Study: 31601479
Drug: Immediate exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate exercise (IE, during taxane chemotherapy)
Study: 31601479
Drug: Delayed exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed exercise (DE, after chemotherapy)
Study: 18568885
Drug: Oral ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketorolac
Study: 12087928
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination capsule of chloroquine (100 mg) and proguanil (200 mg)
Study: 12087928
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of chloroquine (100 mg) and proguanil (200 mg)
Study: 12087928
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination capsule of chloroquine and proguanil
Study: 12087928
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of chloroquine and proguanil
Study: 10480474
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of nisoldipine ER (20 mg)
Study: 10480474
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of nisoldipine ER (20 mg)
Study: 30822800
Drug: Multimodal pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal pain management protocol (preoperative intravenous acetaminophen, preincision subcutaneous bupivacaine, intraoperative intramuscular ketorolac)
Study: 28325826
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E (800 or 1200 mg of EGCG)
Study: 27275271
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with 970 nm diode laser irradiation
Study: 27275271
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (0.1% triamcinolone acetonide orabase)
Study: 16430195
Drug: Peramivir 400
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Peramivir 400 mg q24h
Study: 16430195
Drug: Peramivir 200
Normalized name: peramivir 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peramivir 200 mg q12h
Study: 16430195
Drug: Peramivir 400
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Peramivir 400 mg once daily
Study: 16430195
Drug: Peramivir 800/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peramivir 800/400 mg once daily
Study: 16430195
Drug: Peramivir 50
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Peramivir 50 mg
Study: 16430195
Drug: Peramivir 200
Normalized name: peramivir 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peramivir 200 mg
Study: 16430195
Drug: Peramivir 400
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Peramivir 400 mg
Study: 16430195
Drug: Peramivir 800
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Peramivir 800 mg
Study: 6364892
Drug: cyclandelate 400
Normalized name: cyclandelate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclandelate 400 mg qid
Study: 31464391
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (ONS) with dietary guidance
Study: 30015629
Drug: L-rhamnose (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-rhamnose (25 g d-1)
Study: 30015629
Drug: L-rhamnose
Normalized name: L-rhamnose isomerase
DrugBank: Rhamnose (DB02961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-rhamnose
Study: 24610876
Drug: Seropositive for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seropositive for HPV-16 antibodies
Study: 24610876
Drug: Seropositive for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seropositive for HPV-18 antibodies
Study: 22932751
Drug: PTH 1‐34
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH 1‐34 (30 μg/kg daily intraperitoneal injections for 14 days)
Study: 21221502
Drug: Food supplements
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplements
Study: 21221502
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no food supplements)
Study: 10470203
Drug: Monoclonal antibody-based
Normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody-based assay for TPA (TPA-M)
Study: 8735197
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of immunological assays with different antibodies
Study: 1662882
Drug: Temafloxacin 200
Normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin 200 or 400 mg once daily for 3 or 7 days
Study: 1662882
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (trimethoprim/sulfamethoxazole 160 mg/800 mg, ciprofloxacin 250 mg, or norfloxacin 400 mg, each given twice daily for 7-10 days)
Study: 7082776
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral tablet
Study: 7082776
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intramuscular injection
Study: 7082776
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intramuscular injection
Study: 7082776
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous injection
Study: 31931172
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OAC) treatment
Study: 31931172
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (OAC plus antiplatelet)
Study: 25231632
Drug: Haplotype G-5G-T
Normalized name: (T,G)-A-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haplotype G-5G-T
Study: 25231632
Drug: Haplotype A-4G-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haplotype A-4G-G
Study: 22314555
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (AHG absent)
Study: 18654768
Drug: Escitalopram 5
Normalized name: escitalopram 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 5 mg b.i.d after 1 week
Study: 18654768
Drug: Single-dose omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose omeprazole 40 mg
Study: 12867221
Drug: IV gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV gatifloxacin 400 mg QD with option for oral stepdown gatifloxacin
Study: 12867221
Drug: IV ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ceftriaxone 1 or 2 g QD (with or without erythromycin or clarithromycin) with option for oral stepdown clarithromycin
Study: 29887243
Drug: Chemoradiotherapy (CRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (CRT) with daily low-dose carboplatin
Study: 28391237
Drug: Low vitamin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vitamin D levels (< 50 nmol/L)
Study: 28391237
Drug: Normal vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal vitamin D levels (≥ 50 nmol/L)
Study: 23204255
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (early PN)
Study: 23204255
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (late PN)
Study: 23204255
Drug: Lowest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest dose of macronutrients
Study: 23204255
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of macronutrients (administered parenterally or enterally)
Study: 23204255
Drug: Early combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early combined parenteral/enteral nutrition
Study: 21169833
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with stem cell rescue
Study: 21169833
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy without stem cell rescue
Study: 18047500
Drug: Rizatriptan 10
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 10 mg ODT
Study: 9315420
Drug: Femcap with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femcap with nonspermicidal lubricant (K'Y gel)
Study: 3946803
Drug: Thiopental (39.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (39.5 mg/kg)
Study: 31229533
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (coiling)
Study: 1680893
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion (250 micrograms/h for 24 hours)
Study: 1680893
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of somatostatin and balloon tamponade
Study: 10896067
Drug: Intravenous secretin
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous secretin (2 U/kg) plus placebo (Group 1)
Study: 10896067
Drug: Intravenous secretin
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous secretin (2 U/kg) plus cholecystokinin (0.02 microg/kg) (Group 2)
Study: 9378668
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment (Nux vomica D200, Okoubaka D3, Tuberculinum D200, Barium jodatum D4, Barium jodatum D6)
Study: 8317516
Drug: OC3 (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC3 (35 micrograms ethinyl estradiol and 0.5 mg norethindrone)
Study: 8317516
Drug: OC2 (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC2 (35 micrograms ethinyl estradiol and 1.0 mg norethindrone)
Study: 24528935
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyaluronate and diquafosol
Study: 22238339
Drug: DepoFoam bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoFoam bupivacaine (133 or 266 mg)
Study: 22238339
Drug: bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine HCl (75 mg)
Study: 22238339
Drug: bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine HCl (200 mg)
Study: 22238339
Drug: DepoFoam bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoFoam bupivacaine (532 mg)
Study: 19279561
Drug: NIC gum
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NIC gum treatment
Study: 17192761
Drug: STS 6
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: STS 6 mg/24 hr
Study: 15923689
Drug: Zinc and
Normalized name: Zinc and/or zinc compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc and copper supplementation (40 mg of zinc sulfate and 5 mg of copper sulfate in ORS)
Study: 15923689
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 mg of standard ORS powder in ORS)
Study: 12414874
Drug: Aspirin (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (a nonspecific COX‐1 and COX‐2 inhibitor)
Study: 12414874
Drug: Diclofenac (predominantly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (predominantly a COX‐2 inhibitor)
Study: 12414874
Drug: Celecoxib (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (a specific COX‐2 inhibitor)
Study: 755865
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of autogenic training and skin temperature feedback
Study: 31127818
Drug: Carbohydrate or
Normalized name: PHOSPHORATED CARBOHYDRATE ORAL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate or protein delivered in gastric release formulations
Study: 31127818
Drug: Fat delivered
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat delivered in gastric release formulations
Study: 29220633
Drug: treatment‐as‐usual condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment‐as‐usual condition
Study: 26011337
Drug: Postoperative parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative parenteral nutrition (PN)
Study: 23420502
Drug: Oral ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ergocalciferol
Study: 21289227
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D (25(OH)D) levels measured in quartiles and clinical cut points (<50, 50-<75, ≥ 75 nmol/L)
Study: 22078129
Drug: Rizatriptan 10-mg
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 10-mg ODT
Study: 11679918
Drug: Diphtheria-tetanus toxoids-acellular
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus toxoids-acellular pertussis (DTaP) combined with PRP-tetanus conjugate (PRP-T) vaccine
Study: 7841965
Drug: Both drug
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drug and surgical treatment (endometrial resection or hysterectomy)
Study: 30251598
Drug: Aripiprazole 10
Normalized name: aripiprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 10 mg single oral dose
Study: 27440518
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg edoxaban
Study: 27440518
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg edoxaban
Study: 23448939
Drug: Phytonutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytonutrient supplement (blended fruit and vegetable juice powder concentrate)
Study: 23448939
Drug: Phytonutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytonutrient supplement
Study: 20873911
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) group (n = 42)
Study: 20873911
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) group (n = 74)
Study: 28763413
Drug: Motor-sparing block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor-sparing block (0.5% ropivacaine, 2.5 μg/mL of epinephrine, 10 mg of morphine, and 30 mg of ketorolac)
Study: 28763413
Drug: Periarticular infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular infiltration (0.3% ropivacaine, 2.5 μg/mL of epinephrine, 10 mg of morphine, and 30 mg of ketorolac)
Study: 23347176
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg every other day plus folic acid 5 mg daily
Study: 23347176
Drug: Tadalafil 10
Normalized name: tadalafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 10 mg every other day plus placebo daily
Study: 17912163
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (under investigation)
Study: 12786728
Drug: Deodorants containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deodorants containing hydroxycitronellal (0.032-0.32%) applied twice daily
Study: 1761173
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oestriol applied daily intravaginally over 3 weeks
Study: 1761173
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg oestriol applied daily intravaginally over 3 weeks
Study: 24366034
Drug: Combination (weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (weight loss and sodium reduction)
Study: 23158073
Drug: nCPAP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: nCPAP + antihypertensive drugs
Study: 20490904
Drug: Hydralazine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine therapy (25 mg b.d., for 1 week)
Study: 20490904
Drug: Hydralazine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine therapy
Study: 18300848
Drug: Valsartan 80-160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80-160 mg/day
Study: 16113620
Drug: Atomoxetine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine monotherapy
Study: 16113620
Drug: Combined atomoxetine/fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined atomoxetine/fluoxetine therapy
Study: 16113620
Drug: Fluoxetine (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (with concomitant atomoxetine)
Study: 12885837
Drug: 30-minute infusion
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute infusion of gemcitabine (2,200 mg/m2)
Study: 12885837
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose rate (FDR) infusion of gemcitabine (1,500 mg/m2 over 150 minutes)
Study: 10389788
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 8 mg
Study: 8782169
Drug: Selective adsorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective adsorption followed by intravenous IgG
Study: 6344265
Drug: Diazepam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.05 mg/kg
Study: 30642575
Drug: BET inhibitor
Normalized name: BET INHIBITOR TEN-010
DrugBank: RO-6870810 (DB15151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BET inhibitor (JQ1)
Study: 29551706
Drug: Glecaprevir/pibrentasvir (G/P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/pibrentasvir (G/P) for 8 weeks (300 mg/120 mg)
Study: 29551706
Drug: Glecaprevir/pibrentasvir (G/P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/pibrentasvir (G/P) for 12 weeks (300 mg/120 mg)
Study: 22828556
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ringer's Lactate 10ml/kg and Hydroxyethylstarch-6% 4ml/kg (Group-RLH)
Study: 17490966
Drug: Trace element
Normalized name: trace elements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trace element supplementation (copper, selenium, zinc) administered intravenously for 14-21 days.
Study: 15561864
Drug: BB-83698 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BB-83698 (10 to 475 mg single dose)
Study: 8526579
Drug: Carbohydrate-rich drink
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-rich drink (400 mL, 285 mOsm/kg, 12.0% carbohydrates)
Study: 8526579
Drug: Water (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (400 mL)
Study: 26336930
Drug: Belimumab treatment
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab treatment
Study: 25403582
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg every 6 months for 3 years) plus tamoxifen (20 mg/day)
Study: 25403582
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg every 6 months for 3 years) plus anastrozole (1 mg/day)